

MEDIA FACT SHEET

Orsiro Ultrathin Drug-Eluting Stent System

October 2019

A stent is a small mesh tube used to treat narrowed arteries. It is placed in an artery as part of percutaneous coronary intervention, a procedure to restore blood flow through narrowed or blocked arteries. After implantation, the stent helps supporting the inner wall of the artery in the months or years after the procedure¹.

Drug-eluting stents like Orsiro² are coated with an anti-proliferative drug that is slowly and continuously released. Orsiro is designed to treat de novo coronary stenosis – new lesions that occlude coronary arteries – and in-stent restenosis – lesions that have reformed inside a stent. Orsiro reopens the artery and releases a controlled dose of a limus drug that helps prevent re-narrowing of the artery (restenosis).

Orsiro's safety and efficacy

The ultrathin Orsiro drug-eluting stent (DES), launched in the CE-market in 2011 and approved by the FDA in 2019, features the latest development in BIOTRONIK stent technology – a unique solution that combines passive and active components. proBIO passive coating encapsulates the stent and minimizes interaction between the metal stent and the surrounding tissue.

BIOlute active coating contains a highly biocompatible polymer that delivers a limus drug via a bioabsorbable matrix. These coatings are layered on top of the PRO-Kinetic Energy stent platform, which has a strong and flexible ultrathin strut design and is highly deliverable.

Safety, efficacy and clinical performance of the Orsiro stent have been investigated in clinical studies with more than 48,500 patients enrolled to date.³ Significantly lower rates of target lesion failure (TLF) and target vessel myocardial infarction (TV-MI) were observed at 12 months in the BIOFLOW-V study.⁴ In addition, according to newly released data from the BIOSTEMI trial, Orsiro has demonstrated superiority over DP-EES* with respect to TLF rates at 12 months in patients presenting with ST-segment elevation myocardial infarction (STEMI).⁵

Orsiro is the first current generation DES with a proven superiority over another current generation DES in STEMI patients.

For more information please visit www.orsiro.com.

References:

1 The US National Heart, Lung and Blood Institute: www.nhlbi.nih.gov/health/health-topics/topics/stents

2 Orsiro is a trademark or registered trademark of the BIOTRONIK group of companies

3 Status: January 2019

4 Kandzari D et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents. JACC. 2018 Dec 17;72(25):3287-97.

5 Iglesias JF et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. The Lancet. Published online: September 2, 2019. DOI: [https://doi.org/10.1016/S0140-6736\(19\)31877-X](https://doi.org/10.1016/S0140-6736(19)31877-X)


*Durable Polymer Everolimus Eluting Stent

For indications please see Instructions For Use.

Disclaimer: Content applicable only outside the US



BIOTRONIK at a Glance

At BIOTRONIK , patient well-being is our top priority and has been for more than 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.



Global Impact

Physicians have implanted more than 20 million BIOTRONIK devices in over 100 countries.



Business Areas

BIOTRONIK is active in cardiac rhythm management, electrophysiology, vascular intervention and neuromodulation.



R&D

BIOTRONIK is headquartered in Berlin and researches, develops and manufactures exclusively in the high-tech countries of Germany, Singapore, Switzerland and the United States.

All critical components are manufactured in-house to ensure uncompromised safety, the highest quality and reliability. One in five employees at Berlin headquarters work in research and development.

Find us on Social Media

